Fred Schwarzer - 12 Mar 2022 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Reporting relationship: CEO and President, Director
Issuer ticker: IGMS
Reported as of: 12 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Mar 2022, 20:53:12 UTC
Prior SEC filing: 17 Nov 2021
Next SEC filing: 17 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Misbah Tahir, by power of attorney

Key filing fact

Fred Schwarzer filed Form 4 for IGM Biosciences, Inc. (IGMS) on 15 Mar 2022.

Key facts

This page summarizes Fred Schwarzer's Form 4 filing for IGM Biosciences, Inc. (IGMS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Mar 2022, 20:53.

Change

Previous filing in this sequence was filed on 17 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IGMS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +350,000
Change %
Price: $0.000000
Shares after: 350,000
Date: 12 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 350,000
Exercise price: $17.11
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48 of the shares subject to the option shall vest on April 12, 2022 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.